259 related articles for article (PubMed ID: 24813230)
1. Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression.
Xie J; Liu M; Li Y; Nie Y; Mi Q; Zhao S
Cell Mol Immunol; 2014 Sep; 11(5):495-502. PubMed ID: 24813230
[TBL] [Abstract][Full Text] [Related]
2. miR-20a regulates sensitivity of colorectal cancer cells to NK cells by targeting MICA.
Tang S; Fu H; Xu Q; Zhou Y
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 30988067
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma.
Al-Abdallah A; Jahanbani I; Mehdawi H; Ali RH; Al-Brahim N; Mojiminiyi O; Junaid TA
Exp Mol Pathol; 2020 Apr; 113():104379. PubMed ID: 31935378
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis.
Ou ZL; Luo Z; Wei W; Liang S; Gao TL; Lu YB
RNA Biol; 2019 Nov; 16(11):1592-1603. PubMed ID: 31402756
[TBL] [Abstract][Full Text] [Related]
5. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis.
Li K; Mandai M; Hamanishi J; Matsumura N; Suzuki A; Yagi H; Yamaguchi K; Baba T; Fujii S; Konishi I
Cancer Immunol Immunother; 2009 May; 58(5):641-52. PubMed ID: 18791713
[TBL] [Abstract][Full Text] [Related]
7. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
8. Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer.
Shen J; Pan J; Du C; Si W; Yao M; Xu L; Zheng H; Xu M; Chen D; Wang S; Fu P; Fan W
Cell Death Dis; 2017 Apr; 8(4):e2740. PubMed ID: 28383557
[TBL] [Abstract][Full Text] [Related]
9. miR-20a inhibits the killing effect of natural killer cells to cervical cancer cells by downregulating RUNX1.
Zhu SY; Wu QY; Zhang CX; Wang Q; Ling J; Huang XT; Sun X; Yuan M; Wu D; Yin HF
Biochem Biophys Res Commun; 2018 Oct; 505(1):309-316. PubMed ID: 30249397
[TBL] [Abstract][Full Text] [Related]
10. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
11. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
13. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
14. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
15. Host immune system gene targeting by a viral miRNA.
Stern-Ginossar N; Elefant N; Zimmermann A; Wolf DG; Saleh N; Biton M; Horwitz E; Prokocimer Z; Prichard M; Hahn G; Goldman-Wohl D; Greenfield C; Yagel S; Hengel H; Altuvia Y; Margalit H; Mandelboim O
Science; 2007 Jul; 317(5836):376-81. PubMed ID: 17641203
[TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
17. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer S; Groh V; Wu J; Steinle A; Phillips JH; Lanier LL; Spies T
Science; 1999 Jul; 285(5428):727-9. PubMed ID: 10426993
[TBL] [Abstract][Full Text] [Related]
18. The antitumour effect of {gamma}{delta} T-cells is enhanced by valproic acid-induced up-regulation of NKG2D ligands.
Suzuki T; Terao S; Acharya B; Naoe M; Yamamoto S; Okamura H; Gotoh A
Anticancer Res; 2010 Nov; 30(11):4509-13. PubMed ID: 21115900
[TBL] [Abstract][Full Text] [Related]
19. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of miR-302c and miR-520c by 1,25(OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicity.
Min D; Lv XB; Wang X; Zhang B; Meng W; Yu F; Hu H
Br J Cancer; 2013 Aug; 109(3):723-30. PubMed ID: 23820258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
